Guilin Sanjin Pharmaceutical News

Guilin Sanjin (002275): Steady growth and recovery trend is obvious

Debang SecuritiesOct 31 15:22

Guilin Sanjin (002275): Q2 performance exceeded expectations, and demand for core products was supported

Sep 1 00:00

Guilin Sanjin (002275): Q2 performance improved markedly month-on-month, adhering to the strategy and consolidating steady growth

Aug 30 00:00

Guilin Sanjin (002275): Q1 performance returns to normal, high dividend policy is expected to continue

May 6 00:00

Guilin Sanjin (002275): Performance is in line with expectations, and the two wings move forward steadily

Apr 28 15:36

Guilin Sanjin (002275): After deducting the rapid growth of non-net profit, the chairman plans to increase his shareholding, demonstrating confidence in development

Mar 5 00:00

Guilin Sanjin (002275): The main business is growing steadily, and the subsidiary is expected to reduce losses

德邦證券Sep 2, 2023 00:00

Guilin Sanjin (002275): Industrial income is rising steadily, and Shanghai Sanjin's losses are expected to be drastically reduced

天風證券Aug 25, 2023 15:36

Guilin Sanjin (002275): The advantages of traditional Chinese medicine are obvious, and the two-wing strategy is expected to be implemented

天風證券Jul 27, 2023 18:06

Guilin Sanjin (002275): The traditional Chinese medicine business grew rapidly in the first quarter, and the Sanjin brand continued to grow steadily and far-reaching

華安證券Apr 27, 2023 00:00

Guilin Sanjin (002275): “Time-honored brands” at the beginning of revaluation

浙商證券Apr 14, 2023 00:00

Guilin Sanjin (002275): An underrated brand of traditional Chinese medicine inspired and revitalized

德邦證券Mar 28, 2023 16:37

Guilin Sanjin (002275) 2022 Third Quarter Report Review: Steady Growth in Performance and Increased Brand Leadership

東方財富證券Oct 31, 2022 00:00

Guilin Sanjin (002275): The increase in profitability is obvious, and the performance of long-established brands is growing better

東方財富證券Aug 24, 2022 13:47

Guilin Sanjin (002275) Review Report: Performance is steady and far-reaching in line with expectations

華安證券Aug 18, 2022 00:00

Guilin Sanjin (002275): Regional brands of traditional Chinese medicine leaders are growing steadily and new businesses are starting a second growth curve

華安證券May 14, 2022 00:00

Guilin Sanjin Gold (002275): Foreign Investment Rating (FIR)

中盛在線Jan 10, 2020 00:00

Guilin Sanjin (002275) In-depth research: in-depth exploration of brand value growth is expected to accelerate in the next three years

申萬宏源研究Dec 28, 2017 00:00

Guilin Sanjin (002275) KuaiBao comments: slow growth in the fourth quarter is a drag on performance

華融證券Mar 2, 2017 00:00

Guilin Sanjin (002275) follow-up comments: three quarterly reports meet expectations of new drug research and development progressing smoothly

華融證券Oct 24, 2016 00:00